AGILeBiotics is developing of novel antibiotics to treat multi-drug resistant (MDR) Gram-negative infections. Our main focus is to find new antibiotic candidates active against carbepenem-resistant Enterobacteriaceae (CRE) infections. In addition, AGILeBiotics is motivated in finding novel treatment options for MDR tuberculosis and cystic fibrosis.

Currently, we have three drug candidates, i.e. 
ABX-605, ABX-245 and ABX-395, in pre-clinical development, which show exceptional in vitro and in vivo activity against clinical isolates of multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae.